Drug intelligence / Profile preview

RMX-VH

Development stage: Unknown
Lead developer: Radiomedix
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**RMX-VH** is a radiotracer ligand developed by RadioMedix and Vect-Horus that targets the **low-density lipoprotein receptor (LDLR)**, overexpressed in cancers such as glioblastoma multiforme (GBM) and pancreatic ductal adenocarcinoma (PDAC). It enables crossing of the blood-brain barrier for effective tumor imaging, serving as a companion diagnostic for future targeted alpha therapy (TAT). Labeled forms include **68Ga-RMX-VH** (PET imaging) and **203Pb-RMX-VH-PIB** (SPECT imaging), with preclinical and exploratory clinical studies demonstrating favorable targeting in vitro, in vivo, and in patients.[1][2][3][4]

Other names: RMX-VH

Targets

LDLR (Low-density lipoprotein receptor)

Beyond the preview

Go deeper on RMX-VH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RMX-VH.

Explore the full profile